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Abstract 
Introduction: Treatment of malignant pleural mesothelioma (MPM) remains a clinical 
challenge. The aim of this study was to identify selection factorsfor allocation of MPM 
patients to multimodal therapy based on survival data from 12 years of experience.  
Methods: Eligible patients had MPM of all histological subtypes with clinical stage T1-3 N0-
2 M0. Induction chemotherapy consisted of cisplatin/gemcitabine (cis/gem) 
orcisplatin/pemetrexed (cis/pem), followed by extrapleural pneumonectomy 
(EPP).Multivariate analysis was performed to assess independent prognosticators for overall 
survival (OS). A Multimodality Prognostic Scorewasdeveloped based on clinical 
variablesavailable before surgery. 
Results: From May 1999 to August 2011, 186 MPM patients were intended to be treated with 
induction chemotherapy followed by EPP. Hematologic toxicity was significantly less 
frequent after cis/pemcompared to cis/gem, but no difference in response or OS between the 
regimens.128 patients underwent EPP with a30-day mortalityof4.7%. 52% percent of the 
patients received adjuvant radiotherapy. The median OSof patients undergoing EPP was 
significantly longer with 22months (95%CI:20-24) as compared to 11 months (9-12) for 
patients treated without EPP.Aprognostic score was defined considering tumor 
volume,histology, CRP,andresponsetochemotherapythat identified patient groupsnot 
benefittingfrom multimodality treatmentwhich was confirmed in an independent cohort. 
Conclusion: Patients receiving induction chemotherapy followed by EPP for MPM of all 
histological subtypes and irrespective of nodal statusshowed a median survival of 22months.  
A prognostic score is proposed to help patient allocation for surgery after validation in an 
independent cohort. 
Keywords: extrapleural pneumonectomy - inductionchemotherapy – selection score 
malignant pleural mesothelioma –multimodality therapy 
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Treatment of malignant pleural mesothelioma (MPM) patients continues to be a clinical 
challenge. Advances overthe last decades, including better understandingof tumor biology and 
improved quality of complete macroscopic resection, have changed the scepticalattitude 
towards this disease. This is a result of rising experiences with multimodality (MM) treatment 
strategies associated with a median survival up to 59 months in selected patients1-4. One of the 
most challenging questions is the selection of patients for aggressive treatment, considering 
the limited prognosis of MPM patients in general.To identify patient subgroupsnot benefitting 
from MM therapy and therefore to exclude those from surgery would be desirable. 
In the presentreport we analysedone of the largest series ofconsecutively treated patients with 
induction chemotherapy (cis/gemor cis/pem) followed by extrapleural pneumonectomy 
(EPP). We decided to establisha new Multimodality Prognostic Scoreusing clinical variables 
for the decision to perform surgery. 
 
Materials and Methods 
Patients and Indications 
MPM patients treated at the Division of Thoracic Surgery of the University Hospital 
Zurichbetween May 1999 andAugust 2011were analysed. Eligibility criteria were 
biopsyproven MPM of any histological subtype, clinical stage T1-3, N0-2, M0 disease5, and 
resectabilitybased on the decision of aninterdisciplinary tumorboard including a thoracic 
surgeon. Other inclusion criteria were as described previously2. For staging procedures 
patients underwent CT scan of the chest and / or PET-CT scan before and after 
chemotherapy.In 81% videomediastinoscopywas performed for mediastinal staging to rule out 
N3 disease. Patients treated as part of theSAKK multicentre study(SAKK 17/04; 
ClinicalTrials.gov Identifier: NCT00334594) (n=45) are also included in the analysis. The 
treatment protocol was performed in compliance with the principles of good clinical practice, 
the Helsinki declaration, and institutional guidelines. 
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Treatment Plan 
Induction chemotherapyconsisted of three cycles of cisplatin and gemcitabine (cis/gem) or 
since March 2003 of cisplatin and pemetrexed(cis/pem) as described previously 6.  
Surgery(EPP) was performed within 6 weeks after completion of the last cycle of 
chemotherapy as described previously6.Final pathological staging was carried out following 
the TNM staging system7.  
Radiotherapy was performed according to definite tumor stage and if high-risk 
zonesweredefined by the operating surgeon or according to SAKK 17/04treatment protocol. 
Different radiation techniques and doses were applied over the years (3D-conformal 
radiotherapy and IMRT).Overall 67 patients (52%) received adjuvant radiotherapy (12 
patients in IMRT technique) after induction chemotherapy and EPP. 
Analysis of data 
Data were collected from medical records archived in our data management program KISIM 
Version 4.816 (retrospective analysis 1999-2004, prospective documentation since 2004). 
All consecutive patients intended to be treated with inductionchemotherapy and EPP were 
retrospectively analysed for toxicity of chemotherapy and survival. Toxicities assessed were 
grade °III/°IVhaematological toxicity, grade °III/°IVnephrotoxicity, and unscheduled 
hospitalizations due to chemotherapy.  
Response to chemotherapy was evaluated by modified RECIST criteria by one independent 
observer (T.F)8 in 128 cases with available pre and post chemotherapy imaging as was the 
tumor volume (T.F., D.N.-K.) which was assessed by the help of a semi-automated dedicated 
software (Myrian®; Intrasense, Paris, France) asdescribed previously 9. 
Patients undergoing EPP after induction chemotherapy were evaluated for putative prognostic 
factors for overall survival (OS)according to Simms et al.10. Continuous variables were 
dichotomized by data driven approaches. The putative factors described for an association 
with outcomewere: sex, age (61 years vs. >61 years), exposure to asbestos, smoking, weight 
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loss (10% body weight), chest pain, ECOG-Performance status (0 vs. 1 vs. 2), white blood 
cell count (9.6 G/l vs. >9.6 G/l), platelets count (400 G/l vs. >400 G/l), haemoglobin 
amount ( 117 g/l vs.>117 g/l), CRP level (30 mg/l vs. >30 mg/l), LDH (480 U/l vs. >480 
U/l), cN2 assessed by mediastinoscopy, pre-chemotherapy histology and definitive histology 
(epithelioid vs. non-epithelioid), extend of resection (R0/1 vs.R2), RECIST factor (partial 
remission (PR)orstable disease (SD) vs. progressive disease (PD)),tumor volume pre and post 
chemotherapy (500 ml vs. >500 ml), ypT-stage, nodal status (ypN0 vs. ypN1/2), lymph node 
ratio (positive lymph nodes: regional and mediastinal/ all resected lymph nodes), trocar 
infiltration, IMIG-stages, regimen of chemotherapy (cis/gem vs. cis/pem), radiotherapy 
(adjuvant radiotherapy vs. no adjuvant radiotherapy), EORTC-Score (European Organization 
for Research and Treatment of Cancer-classification)11. 
Statistical analysis was carried out using the software package SPSS for Windows, 20.0.0 
(SPSS Inc., Chicago, IL, USA). Categorical data are given as total number and percentages 
and were compared between groups using Fisher’s exact test. Continuous data are given as 
median with range. 
Median survival time was assessed by Kaplan-Meier curves and the influence of the different 
prognostic factors was analysed by log rank-test. Survival time was calculated as time 
between application of the first cycle of chemotherapy and time point of death or last follow-
up. For comparison of continuous variables in two independent groups we used the Mann-
Whitney U test.  
Two-sided p-values lower than 0.05 were considered statistically significant. In order to study 
the joint influence of the different factors on survival in a multivariate analysis, a stepwise 
Cox regression was performed including all prognostic factors being significant in the 
univariate analysis excepting factors being represented already in the score. 
Based on our clinical experience, results from the literature12, 13,and prognosis relevant factors 
derived from our survival analyses, we established a new Multimodality Prognostic 
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Score(MMPS) to identifysubgroups of patients not benefitting from MM therapy. The score 
contains 4 items with a maximum possible score of 4 if the patient presented all four 
conditions and 0 if none were present: Tumor volume before chemotherapy >500 ml, non-
epithelioid histological subtypein the diagnostic biopsy before chemotherapy, CRP value >30 
mg/lbefore chemotherapy,and progressive diseaseafter chemotherapy. A second score using 
the same variables without progressive disease after chemotherapy was tested in order to 
evaluate factors being available at initial patient evaluation. 
The predictive power of our new MMPS was compared to the existing EORTC score at one 
and two years using time-dependent ROC curve estimation using the R package 
timeROC(version0.2) 14.The prognostic impact of MMPSwas further evaluated in the 
intention to treat cohort without surgery (n=37)as well as in an independent cohort of patients 
treated at the Division of Thoracic Surgery, University Hospital in Vienna (n=22) with the 
same treatment approach of induction chemotherapy followed by EPP. 
 
Results 
From 1st May 1999 until August 2011, 186out of 323 MPM patients wereeligible and agreed 
to undergo induction chemotherapy followed by EPP(Intention to treat (ITT) group):The 
initial 63patients (34%) received three cycles of cis/gemandsince March, 2003,122patients 
(65%) were treated withcis/pem chemotherapy,onepatient received cisplatin plus vinorelbine. 
There was significantly less °III/°IVhaematological toxicity at day 8 after 
cis/pemchemotherapy (p<0.0005)in comparison to cis/gem, whilethere wereno significant 
differences in nephrotoxicity or unscheduled hospitalisations.Response after chemotherapy 
wasassessed in 128cases:60patients had stable disease (SD),33progressive disease (PD), and 
35partial response (PR), no complete response was observed. There was no significant 
difference in response between the two chemotherapy regimens: 66% cis/gem with SD or PR 
versus77% cis/pem(p=0.7). Also the changes of tumorvolume after chemotherapy did not 
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differ significantly (cis/gem 81% with tumor volume 500 ml vs. 86% cis/pem(Mann-
Whitney U Test, p=0.8). 
The median follow-up time of the ITT group(n=186) was 18months (1-123). Sixpatients were 
lost to follow up, leading to 97% complete follow-up. Median OSwas 19 months (95% CI: 
15-23). Patients with progressive disease (n=33) had a significant shorter median OS(14 
months (95% CI: 9-18)) in comparison to patients with PR/SD (n=95) (22 months (95% CI: 
17-26)) (p=0.02) (Figure 1A).The chemotherapy regimen applied had no impact on OS 
(Figure 1B). 58 patients were excluded from radical resection after induction chemotherapy. 
The most frequent reason for exclusion was multi-level chest wall infiltration (n=26),another 
reason was progressive disease (n=18) (See supplementary figure 1).  
128patients underwent EPP after completion of 3 cycles of chemotherapycorresponding to 
a resectability rate of 69%. The following analysisis based on thispopulation; patients’ 
characteristicsare listed in table1. EPP was performed by three different surgeons in a median 
operation time of 360min (230–580 min). The mediastinal lymphadenectomy resulted in a 
mean number of 11 resected lymph nodes (regional and mediastinal) (SD ±9). The median 
duration of hospital stay was 15days (6–39). 6patients died within the first 30 days after 
operation (30-day mortality 4.7%) due to massive central pulmonary embolism (n=1), septic 
multiorgan failure (n=1), acute heart failure (n=2), pneumonia (n=1),and partial gastric 
necrosis due to herniation after patch failure (n=1). The latest case of 30 day mortality 
was2011after a period of 4years without any perioperative deaths.Major postoperative 
morbidity(pulmonary embolism, bleeding, bronchopleural fistula, empyema, patch failure) 
occurred in 47cases (37%). The median OS for all 128 patients was 22 months (95% CI: 20-
24) and significantly differed from the survival of the patients treatedwith chemotherapy 
alone(p<0.0005) (Figure 2) which might be attributed to the effect of surgery as well as to 
patient selection.Thesignificant results of univariate analyses ofOS are listed in table 2 and 
entered multivariate analysis (Table 3).  
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Side effects of radiotherapy included dysphagia (n=16), nausea (n=26), emesis (n=19), 
radiation dermatitis (n=9), fatigue (n=17), but also more important complication such as 
esophagitis (n=6). 
In addition to the independent prognosticators of our multivariate analysis CRPand 
RECIST,we includedtumor volume and histological subtype into our proposed 
MMPSaccording to reports from the literature12, 15. 
The MMPSrevealed that patients with a score >3had a significantly shorterOS(p<0.0005) 
(Figure 3A). The same was observed using the score without the response variable (data not 
shown).Multivariate analysis including our MMPSrevealed that the score was a strong 
independent prognosticator (table 3). The score was tested also in patients of the ITT 
group(n=37) that did not receive EPP after induction chemotherapyand validated in an 
independent cohort being treated with induction chemotherapy followed by EPP at the 
University Hospital Vienna (n=22), both cohorts not being significantly different in terms of 
age, pre chemotherapy volume, pre chemotherapy histological subtype, and RECIST.In these 
two cohorts patients with score 0 showed a significantly longer OS(Figure 3B and 3C), but 
median survival could not be calculated for all scores in the Vienna cohort, because 10 of 22 
patients had to be censored in survival analysis.  
The comparison of the present scores to EORTC score using ROC analysis at two years 
showed that the MMPS (3 and 4 variables) demonstrated a better predictive power for OS 
thanthe EORTC Score (Supplementary figure 2). Similar results were obtained for one year 
(data not shown). 
 
Discussion 
The present analysis isone of the largest series of induction chemotherapy followed by EPP 
and confirms a median survival of 22 months after induction chemotherapy with 
initiallycis/gem and in the later period cis/pem followed by EPP for MPM of all histological 
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subtypes and irrespective of nodal status. From these data we developed aMultimodality 
Prognostic Score considering four clinical variables available before surgery identifying 
mesothelioma-patients most likely not benefittingfrom multimodality treatment,which we 
were not able to demonstrate with existing scores as the EORTC score. 
When we introduced induction chemotherapy followed by EPP as a treatment modality for 
MPM patients 12 years ago, we postulated that upfront chemotherapy may possibly 
downstage the tumor and hence increase resectability of MPM and therefore improve 
survival. In our initial pilot study we observed a promising median overall survival time of 22 
months which was later confirmed by our Swiss multicentre study2. Since then this concept 
has been adapted by multiple other mesothelioma centersworldwide with comparable 
outcome3, 4.However, overall survival for the whole cohort plateaued at nearly 2 years 
(reviewed in Cao et al. 2010 16). This is most likely related to the fact that eligibility criteria 
were wide. In additionpatients’selection became less stringent over time and patients with 
more advanced disease (proportion of pT4 10% in the present cohort) orcomorbidities were 
accepted. This was felt to be justified by the lack of alternatives and the fact that we were able 
to perform this complex treatment with relatively low mortality and morbidity. Patients were 
accepted for induction chemotherapy and later for resection evenifno response to 
chemotherapy occurred. However, our current analysis shows, that such “rescue procedures” 
resulted in no long-term benefit and we might have observed better outcome with less wide 
inclusion criteria. 
The currentanalysis represents12years’ experience with cisplatin-based induction 
chemotherapy followed by EPP in patients with mesothelioma.To our knowledge, although 
not randomized, this is the first series reporting a large cohort of patients who received 
platinum-based chemotherapy in combination with either gemcitabine or pemetrexed 
asinduction chemotherapyfollowed by EPP. In our analysis we focused not primarily on 
identification of prognostic factors based on pathological staging but rather on prognostic 
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factors available at initial patient evaluation.Nowadays well-defined selection criteria for 
mesothelioma treatment would be of key importance, as clinical staging is unreliable in MPM 
and therefore of limited help for patient selection.  
One particular patient subgroup of interest isthe one responding to induction chemotherapy. 
Indeed, the response to chemotherapy significantly influenced OS– 2/3 of the patients 
responded with either PR or SD afterinduction chemotherapy and survived significantly 
longer. Response to chemotherapy turned out to beeven an independent prognosticator in our 
multivariate analysis,which could help to select patients for surgery.The use of cis/gem 
compared to cis/pem had no influence either on response to chemotherapy measured by 
RECIST oron survival. But it was found that toxicity differsbetween the two regimens and 
°III/°IV haematological toxicity was significantly lower after cis/pem. 
Since Pass et al. proposed to use tumor volume as a prognostic factor for mesothelioma 
patients’ survival 13, it has been confirmed by several other groups 12. Modern computer-
based software using chest CT facilitates tumormeasurement in a reliable and reproducible 
way9. In addition, low C-reactive protein level (CRP)was identified as independent 
prognosticator for longer OS. CRP as an easy to measure marker of inflammatory response 
has been validated already in various other cancers as a prognostic marker17, 18. The reason 
why CRP is a prognostic value in cancer patients is not completely understood but might be 
related to higher tumor aggressiveness as it has been shown also for other type of tumors, eg. 
melanomaand was already demonstrated to be prognostic in the context of MPM 19. 
Other prognosticators such as histological subtype ormediastinal lymph node involvement 
which are quite uniformly reported to have an impact on MPM patients’ survival (reviewed in 
Cao et al. 2011 20), were not confirmed as independent prognosticators in our multivariate 
analysis.This was also observed in the retrospective analysis of the IASLC database – the 
biggest dataset with more than 3101 patients from 15 centres. But for obvious reasons, 
theprognostic meaning of a mesothelioma lymph node metastasis in the mediastinum is not 
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comparable to lung cancer given the direct neighbourhood of the primary tumor in the pleura 
to the mediastinum.  
Because histology could not be confirmed as an independent prognostic factor in our analysis 
as well as in different phase II studies2-4, 21-23, we proposethat inclusion of a patient into 
multimodality treatment should not be based on a single factor alone– such as histological 
subtype or lymph node metastasis–but should rather respect a combination of various 
factors.Based on our analysis, our clinical experience with this heterogeneous disease, 
andwith respect to the published literature12, 13, 19,we proposethis“Multimodality Prognostic 
Score” using parameters being available before surgery or at initial patient evaluation. The 
MMPS (using 3 or 4 variables) clearly stratifiedpatients: Patients with score 0 had in all 3 
cohorts tested the longest OS, whereas patients with a score of 3 or higher had OS as dismal 
as untreated MPM patients.Furthermore, this was not only confirmed in our ITT group of 
patients not undergoing EPP, but also in a second independent cohort of patients treated with 
the same protocol in Vienna. 
In the last years a clear trend to replace EPP by (extended) pleurectomy/decortication (P/D), 
especially for early stages, exists.We hypothesize, that this score may be applicable to all 
macroscopic complete resections (MCRs) within a multimodality concept, as a small subset 
of patients excluded from EPP received P/D (n=20) instead and here we could observe a trend 
ofsurvival prognostication by our MMPS score (data not shown). 
Although EORTC Score has been validated in several cohorts24, we were not able to 
demonstrate any significant prognostic impact on OS.This may be explained by our median 
EORTC score which was 0.6 (range 0-2.34) and quite low in comparison to other groups. The 
higher scores in the other groups are probably due to the fact that these cohorts were receiving 
chemotherapy alone in most cases and therefore had advanced disease and worse performance 
status.In comparative ROC analysis our MMPS score performed better than EORTC score. 
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Besides the retrospective analysis of our data and the fact that therefore not all data 
were available for the whole patient cohort, we are aware that AUC of 69% does not qualify 
our MMPS immediately as a predictive test for patient selection. However, confirmation in an 
independent cohort and in a patient cohort intended to be treated warrants further prospective 
evaluation. With a specificity of 100% of Score 3 and 4 (no survivor had this score) and a 
survival resembling untreated MPM patients, we feel that these patients should not be 
recommended to proceed to MCR in a multimodality concept, which will now be further 
evaluated prospectively. 
Conclusion: Overviewing our 12 years’ experience with induction chemotherapy with cis/gem 
and cis/pemfollowed by EPP for MPM patients of all histological subtypes including N2 
disease,we report a median OS close to two years. The non-randomized comparison of both 
chemotherapy regimens showed significant reduced haematological toxicity in favour of 
cis/pem but no advantage in response or overall survival. A new Multimodality Prognostic 
Score was developed and validated in an independent cohort considering clinical variables 
already available before surgerywhich allowsidentification ofmesothelioma-patients who 
would not get any relevant benefit from an intensified therapy. Additionally biological 
markers are intensively explored at our institution. Among these, tumor proliferation index is 
a robust biomarker, and was significantly associated with clinical outcomes and tumor 
volume. We are also validating the previously identifiedprognostic microRNA score 25 in our 
patient cohort. This is particularly interesting as microRNAs are also potential blood based 
biomarkers26. Thus, we may improve the prognostic value by integrating these factors into our 
Multimodality Prognostic Score. The conceptwill be further validated prospectively. 
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Figure legends 
Figure 1: 
Kaplan-Meier curve of overall survival time in months including all patients intended to be 
treated with chemotherapy followed by EPP. (A) Comparison of response to chemotherapy 
using modified RECIST criteria: Median survival time 22 months (95% CI: 17-26) with 
stable disease (SD) or partial response (PR) versus median survival time 14 months (95% CI: 
9-18) with progressive disease (PD). Response data was only available for 128 patients of the 
ITT group.(B) Comparison of chemotherapy regimen applied: Median survival time 21 
months (95% CI: 15-26) with cisplatin / gemcitabine (cis/gem) versus median survival time 
18 months (95% CI: 12-24) with cisplatin / pemetrexed (cis/pem). 
 
Figure 2: 
Kaplan-Meier curve of overall survival time in months of patients treated with induction 
chemotherapy alone vs induction chemotherapy followed by EPP.Median survival time 22 
months (95% CI: 20-24) with EPPversus median survival time 10 months (95% CI: 9-12) 
without EPP. 
 
Figure 3: 
Kaplan-Meier curve of overall survival (OS) in months of the multimodality  prognostic score 
(including 4 variables: tumor volumepre CTX > 500ml, CRP pre CTX > 30mg/l, non-
epithelioid histology in pre CTX biopsy, progressive disease according to modified RECIST 
criteria): (A) patients treated with induction chemotherapy followed by EPP (Zurich). (B) 
Patients of the intention to treat group (Zurich). (C) Patients treated with induction 
chemotherapy followed by EPP (Vienna). 
 
Supplementary figure 1 
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Flowchart of patients referred to University Hospital Zurich with diagnosis of MPM between 
May 1999 and August 2011.  
* 59 patients of 128 had all 4 items of the MMP score available 
** Out of 58 patients excluded to undergo EPP, 26 patients were excluded before and 32 
during surgery. 
 
Supplementary figure 2 
ROC analysis at two years: the Multimodality Prognostic Score (4 variables) demonstrated 
the best predictive power for OS (AUC 0.687 95% CI 0.54−0.835) followed by the 
Multimodality Prognostic Score (3 variables) (AUC 0.677 95% CI 0.538−0.816) and the 
EORTC Score (AUC 0.519 95% CI 0.392−0.646). The differences were not significant.  
MMPS-4: Multimodality Prognostic Score (4 variables) 
MMPS-3: Multimodality Prognostic Score (3 variables) 
EORTC: EORTC score 
AUC: Area under the curve 
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Tables 
Value Number (percent) 
Gender (male)  113  (88%) 
Age (</= 61 years)  67  (52%) 
Side of Disease (right)  72  (56%) 
Asbestos exposure  101 (79%) 
Smoking  66  (52%) 
Weight loss  49  (38%) 
Chest pain  56  (44%) 
ECOG PS* 0 
 1 
 2 
 62  (60%) 
 31  (30%) 
 10  (10%) 
White blood cell count*(> 9.6 G/l)  36  (33%) 
Hemoglobin concentration*( 117 g/l)  23  (21%) 
Platelet count*(> 400 G/l)  43  (40%) 
CRP level*(> 30 mg/l)  46  (44%) 
EORTC score*(> 1.15)  40  (48%) 
Histologigal subtypepre chemotherapy Epithelioid 
 Sarcomatoid 
 Biphasic 
 102  (80%) 
 4  (3%) 
 21  (17%) 
Mediastinoscopy  107  (84%) 
cN2 at mediastinoscopy  8  (7%) 
Chemotherapy cis / gem 
 cis / pem 
severe side effects 
hemotoxicity 
nephrotoxicity 
hospitalisation 
 47 (37%) 
 81  (63%) 
 34 (27%) 
 19  (15%) 
 8 (6%) 
 11 (9%) 
RECIST* Partial regression 
 Stable disease 
 Progressive disease 
 33  (36%) 
 34  (37%) 
 25  (27%) 
Tumor volumepre chemotherapy* (> 500 ml)  7  (10%) 
Tumor volumepost chemotherapy* (> 500 ml)  7  (9%) 
Surgery  major morbidity 
 30 day mortality 
 47 (37%) 
 6 (5%) 
Resection* R0/R1 
  R2 
 116 (95%) 
  
 6  (5%) 
Histotypepost chemotherapy Epithelioid 
 Sarcomatoid 
 Biphasic 
 80 (63%) 
 4  (3%) 
 44 (34%) 
ypT stage 1 
 2 
 3 
 4 
 11  (9%) 
 40  (31%) 
 64  (50%) 
 13  (10%) 
ypN stage 0 
 1 
 2 
 82  (64%) 
 16  (13%) 
 29  (23%) 
IMIG 1 
 2 
 3 
 4 
 11  (9%) 
 29  (23%) 
 75  (58%) 
 13  (10%) 
Trocar infiltration* 
 24  (22%) 
Adjuvant radiotherapy 
Side effects 
 67  (52%) 
 32 (48%) 
 
Table 1: Patients’ characteristics of the group receiving induction chemotherapy and EPP (n=128).  
* Data were not available for all 128 patients  
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Factor Median survival in months (95% CI) P 
OS Age  61 years:  20  (16-25) 
 >61 years:  23  (19-28) 
0.03 
 CRP level* 
  30 mg/l:  23  (20-26) 
 > 30 mg/l:  17 (9-25) 
0.03 
 RECIST* 
 PR/SD:  22 (21-24) 
 PD:  14 (10-19) 
0.008 
 Multimodality Prognostic Score*  Score  2:  21  (15-28) 
 Score > 2:  4  (3-5) 
 < 0.0005 
 ypT-stage   ypT1:  39  (13-66) 
 ypT2:  23  (20-25) 
 ypT3:  22  (17-26) 
 ypT4:  15  (9-20) 
0.02 
 nodal status (ypN0 vs. ypN1/2)  ypN0:  23  (20-27) 
 ypN1/2:  19  (14-24) 
0.007 
 lymph node ratio  
 0.00:  23  (20-27) 
  0.01:  19  (14-24) 
0.008 
 trocar infiltration*  No:  23  (21-24) 
 Yes:  15  (6-23) 
0.02 
 IMIG-stages  I:  39  (13-66) 
 II:  26  (19-32) 
 III:  22  (19-24) 
 IV:  15  (9-20) 
0.01 
 
 
Table 2: Kaplan Meier overall survival analysis of prognostic factors for 128 patients undergoing 
induction chemotherapy and EPP. 
Data are given as median survival in months (starting from first cycle of chemotherapy 
received) with 95% confidence interval  
* Data were not available for all 128 patients 
Multimodality Prognostic Score including 4 variables: tumor volume pre CTX > 500ml, CRP 
pre CTX > 30mg/l, non-epithelioid histology in pre CTX biopsy, progressive disease 
according to modified RECIST criteria 
CRP: C-reactive protein, PR: partial response, SD: stable disease, PD: progressive disease 
  
Copyright © International Association for the Study of Lung Cancer. Unauthorized reproduction of this article is prohibited
AC
CE
PT
ED
  21
 
  
HR (95% CI) p 
OS 
MultimodalityPrognostic Score 
(4 variables, Score  2 vs. 
Score > 2) 
 14.1 (4.0-85.1) <0.0005 
 
 
Table 3:   Multivariate Cox regression analysis of prognostic factors with significant influence on 
OS in the univariate analysis, excluding factors being represented in the score. 
  Data are given as hazard ratio with 95% confidence interval 
 Multimodality Prognostic Score including 4 variables: tumor volume pre CTX > 500ml, 
CRP pre CTX > 30mg/l, non-epithelioid histology in pre CTX biopsy, progressive 
disease according to modified RECIST criteria 
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